Background Lung cancer death remains the highest among all malignancies. Gender
differences show women have an increased cancer incidence while men have worse …

Approximately 85% of lung cancer cases are recognized as non‑small cell lung cancer
(NSCLC) with a perilous (13‑17%) 5‑year survival in Europe and the USA. Although tobacco …

Introduction Subgroup analyses from clinical studies have suggested that among patients
with metastatic NSCLC receiving chemotherapy, females may derive less benefit from the …

Estrogen promotes non‑small cell lung cancer (NSCLC) metastasis via estrogen receptor β
(ERβ)‑mediated invasiveness‑associated matrix metalloprotease 2 (MMP2) upregulation …

High ERβ/HER oncogenic signaling defines lung tumors with an aggressive biology. We
previously showed that combining the anti-estrogen fulvestrant with the pan-HER inhibitor …

Recent advances have brought forth the complex interplay between tumor cell plasticity and
its consequential impact on drug resistance and tumor recurrence, both of which are critical …

Purpose: The incidence of lung cancer has dramatically increased in women. Preclinical
data have suggested that combining EGFR–tyrosine kinase inhibitor (TKI) with an …

Simple Summary The study showed that androgen deprivation therapy for a preceding
diagnosis of prostate cancer is associated with prolonged survival among patients who …

Introduction Mounting evidence supports a role for estrogen signaling in NSCLC
progression. We previously reported a seven-gene signature that predicts prognosis in …

Epidermal growth factor receptor inhibitors (EGFRi) have exhibited promising clinical
outcomes in the treatment of various cancers. However, their widespread application has …